When do the patents on EC-NAPROSYN expire, and when will EC-NAPROSYN go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Atnahs Pharma Us	EC-NAPROSYN	naproxen	TABLET, DELAYED RELEASE;ORAL	020067-002	Oct 14, 1994	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Atnahs Pharma Us	EC-NAPROSYN	naproxen	TABLET, DELAYED RELEASE;ORAL	020067-003	Oct 14, 1994	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 18, 2026

EC-NAPROSYN (naproxen) Investment Scenario and Patent/FDA Fundamentals Analysis

Executive summary: EC-NAPROSYN is a branded naproxen product (EC = enteric coated) that sits in the long-established NSAID category. From an IP and regulatory-risk standpoint, the primary investment lever is not “new exclusivity” but exposure to ongoing branded vs generic erosion, market share dynamics, and the remaining protectable patent “edges” around specific formulations, dosing strengths, and manufacturing. For most naproxen products, patent-backed exclusivity has largely lapsed, shifting value to distribution, reimbursement, labeling, and litigation over legacy patents rather than new clinical differentiation.

What is EC-NAPROSYN and how does it compare with other naproxen products?

EC-NAPROSYN is an enteric-coated formulation of naproxen intended to reduce stomach irritation relative to immediate-release NSAID dosing. EC-NAPROSYN competes with other branded and authorized generics of naproxen across multiple strengths and dosage forms, including immediate-release naproxen and other enteric-coated naproxen formulations.

What is the active ingredient and what is the drug class?

Active ingredient: Naproxen
Class: NSAID (propionic acid derivative)
Typical competitive set:
- Immediate-release naproxen tablets (generic and authorized generics)
- Enteric-coated naproxen tablets (generic and authorized generics)
- Alternative NSAIDs (ibuprofen, diclofenac, meloxicam) based on formulary placement

How do enteric-coated naproxen brands typically perform versus immediate-release generics?

Enteric-coated products can maintain marginal pricing power in certain formularies, but the category remains generic-dominated. Investment fundamentals typically hinge on:

Formulary position and tier placement
Pharmacy benefit manager (PBM) contracting
State-level substitution and payer protocols
Package size and strength preference

What patents protect EC-NAPROSYN and how strong is the patent estate?

Featured snippet answer: For naproxen enteric-coated products, the patent estate has historically been dominated by legacy formulation and method-of-use patents that have largely expired. As a result, “current protection” (if any) is most often tied to specific listed patents in FDA Orange Book for particular strengths, dosage forms, or manufacturing/formulation details.

How to map EC-NAPROSYN IP to Orange Book coverage

For an investment-grade view, investors typically track:

Orange Book listed patents tied to the application for each strength
Whether patents are tied to:
- composition/formulation
- method of use (label)
- manufacturing process
Whether those patents are still listed as active and have not expired

How many patents cover naproxen EC products and which types dominate?

In legacy NSAID portfolios, Orange Book listings most often concentrate on formulation/manufacturing improvements rather than fundamental drug substance patents. Without current Orange Book listings for the specific EC-NAPROSYN application and strength mapping, a precise patent count and expiry map cannot be stated.

When does EC-NAPROSYN lose exclusivity?

Featured snippet answer: Naproxen’s core exclusivity has largely run its course; the remaining exclusivity question is usually limited to any still-active, Orange-Book-listed patents for the specific EC-NAPROSYN application and strength.

How exclusivity frameworks typically apply to OTC-to-prescription NSAID lines

For older NSAID brands, exclusivity and barriers usually come from:

Orange Book patents (not marketing exclusivity)
Potential pediatric exclusivity add-ons (if applicable to a specific NDA)
Patent-protected formulation/manufacturing improvements (narrow and strength-specific)

What investor timeline matters most for generic erosion

The practical timeline for valuation is:

The nearest listed patent expiration or invalidation event for relevant strengths
The Paragraph IV litigation posture (if any) tied to those patents
Any FDA labeling or REMS-like constraints (rare for NSAIDs; typically labeling updates rather than exclusivity)

What is the Orange Book status of EC-NAPROSYN?

Featured snippet answer: EC-NAPROSYN is an FDA-reviewed product for which Orange Book listings would define any remaining listed patents and their expiry dates.

What the Orange Book normally tells investors

NDA or ANDA linkage
Listed patents with:
- patent numbers
- patent expiration dates
- exclusivity type categories (where applicable)
30-month stay triggers if a Paragraph IV is filed and not settled

Commercial impact of Orange Book status

If no active listed patents remain, generic entry risk is structurally higher.
If active patents exist for certain strengths, entry risk becomes more granular and litigant-specific.

Are there any Paragraph IV challenges for EC-NAPROSYN?

Featured snippet answer: Paragraph IV challenges are the critical entry risk vector for any remaining listed patents. For naproxen enteric-coated products, Paragraph IV activity typically clusters around any remaining late-listed formulation/manufacturing patents rather than the drug substance.

What litigation facts matter for valuation

Investors usually track:

Whether the challenger filed under 505(b)(2) or ANDA for generics
Which patents were challenged (patent-by-patent)
Whether there was a settlement triggering earlier than default generic entry
Whether FDA approval was obtained before/after the 30-month stay

What generic entry risks exist for EC-NAPROSYN?

Featured snippet answer: For entrenched NSAIDs like EC-naproxen, generic entry risk is usually realized through:

Authorized generics already present in the market
Additional ANDA entrants once any late-cycle formulation/manufacturing patents expire
Continued price compression through PBM contracting and multiple-source competition

What drives launch speed and margin erosion

ANDA readiness and manufacturing scale
PBM formulary contracts
Pharmacy distribution channel execution
Any labeling carve-outs required to mitigate patent design-around risks

What typically happens to branded NSAID margins

Branded net price declines after generic saturation.
Stability depends on:
- formulary retention (rebates and contracting)
- patient adherence to enteric-coated profiles
- strength-specific demand

How does EC-NAPROSYN compare with naproxen competitors in patent and commercial exposure?

Competitive landscape framing

EC-NAPROSYN competes in a multi-generic environment:

Enteric-coated naproxen: generic-first
Immediate-release naproxen: generic-first
Other NSAIDs: differentiated by dosing, safety guidance, and formulary preference

Investment implication

If EC-NAPROSYN lacks meaningful remaining patent coverage for key strengths, the investment return depends on:

execution in branded contracting
inventory and supply reliability
managing net price through rebate strategy rather than IP monopoly

What FDA regulatory status applies to EC-NAPROSYN, and is it eligible for 505(b)(2) or ANDA substitution?

What pathway governs generic substitution risk

Generics typically rely on ANDA with bioequivalence to an RLD.
If formulation-specific patents still exist, the generic may face design-around requirements or litigation.

Labeling and safety updates

NSAID labeling changes do not usually reset exclusivity but can affect:

prescriber switching patterns
formulary status
payer restriction rules

What formulations are protected by EC-NAPROSYN patents?

Featured snippet answer: For enteric-coated NSAID brands, protected subject matter (when present) typically includes formulation/manufacturing details specific to the enteric-coating system, dissolution profile, and process controls that are narrower than drug substance patents.

Why formulation-level IP matters for investors

It can delay some generics if the coating composition or release profile is claimed.
It often leads to partial generic entry by strength or by manufacturing approach.
Litigation can be more technical but settlements are common in mature categories.

What manufacturing/IP barriers would block or delay generic copies of EC-NAPROSYN?

Typical manufacturing/IP choke points in enteric-coated NSAID products

Enteric polymer system and coating process
Dissolution specification windows tied to claimed profiles
Controlled-release vs enteric-lag features (if claimed)
Scale-up reproducibility for the coating line

Investor takeaway

If patent barriers exist, they are usually narrow. Once design-around routes are proven, multiple entrants can appear and margins compress quickly.

What patent litigation affects EC-NAPROSYN and how does it influence generic pricing?

What litigation outcomes usually do

Settlement agreements can set an effective “launch date” or limit entry to non-infringing strengths.
Court rulings can remove barriers and accelerate multi-source competition.

How to translate litigation to commercial forecast

Investors typically model:

Probability-weighted launch timing
Price decline after entry
Retention of formulary position for the brand during the litigation window

Are there any licensing deals tied to EC-NAPROSYN?

In mature branded NSAID lines, licensing is more common for:

authorized generic arrangements
settlement-driven rights or co-marketing
manufacturing and supply agreements

No specific licensing deal terms, counterparties, or dates can be provided without verifying the current EC-NAPROSYN Orange Book listing and litigation docket history for the relevant NDA/strengths.

Revenue exposure: how much can EC-NAPROSYN be impacted by generic erosion?

Featured snippet answer: Revenue exposure is structurally high for mature NSAIDs once patent barriers are removed or invalidated. The magnitude depends on:

strength-specific generic penetration
payer contracting cycles
the brand’s remaining prescription share

What matters most for an investment model

Current branded net sales trend (decline speed)
Share retained on enteric-coated versus immediate-release channels
PBM position and rebate intensity
Margin structure after generic competition

How strong is the overall investment thesis for EC-NAPROSYN versus newer therapeutic IP opportunities?

Investment fit for a generic-resilient brand

EC-NAPROSYN can fit an investment thesis focused on:

cash-flow stability from continued demand for enteric-coated naproxen
low R&D burn (relative to IP-heavy novel therapeutics)
resilience to clinical trial risk

Investment weakness

Limited upside from patent creation due to maturity of the active ingredient
High sensitivity to any patent-expiry or settlement outcomes
Rapid margin compression after multiple generics enter

Key Takeaways

EC-NAPROSYN is a mature enteric-coated naproxen brand; the investment question is primarily about remaining Orange Book patent edges and timing of generic erosion, not fresh exclusivity.
Patent-protection, if any, is expected to be strength- and formulation-specific, typically around enteric-coating and manufacturing details.
Commercial fundamentals depend on formulary positioning, PBM contracting, and rebate strategy, with valuation sensitivity to Orange Book status and any Paragraph IV/litigation settlements.
Compared with newer therapeutics, EC-NAPROSYN’s upside is more constrained, but it can support a cash-flow and competitive positioning thesis in a low-clinical-risk NSAID bucket.

FAQs

How do enteric-coated naproxen generics typically design around formulation patents?
What Orange Book patent expiry timing most strongly predicts branded net price declines for NSAIDs?
How do settlements in mature NSAID Paragraph IV cases alter FDA approval and launch dates?
What formulary levers (PBM tier, prior auth, quantity limits) most affect continued EC-naproxen prescribing?
What manufacturing or dissolution-spec issues most often lead to ANDA refusals or labeling re-work for enteric-coated NSAIDs?

References (APA)

FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
FDA. (n.d.). ANDA and 505(b)(2) regulatory pathways overview. U.S. Food and Drug Administration. https://www.fda.gov/

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for EC-NAPROSYN